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Accomplishments

Research Interests
Dr. He has a broad range of research interests in biomedical science
including:
1) to elucidate the roles of major cell signaling pathways in
regulating lineage commitment and terminal differentiation of
mesenchymal stem cells (MSCs);
2) to unravel the molecular and genetic links between MSC
differentiation and bone tumorigenesis;
3) to uncover the essential roles of small regulatory RNAs (esp.
noncoding RNAs) in the development of cancer drug resistance;
4) to develop novel and efficacious gene and/or cell-based
strategies for regenerative medicine and tissue engineering;
and
5) to develop innovative and enabling technologies for basic and
translational research.

Dr. He has published more than 350 peer-reviewed research articles and scientific reviews, many of which appeared in
the top tier journals such as Science, Cell, Nature Genetics, Cancer Research, Genes & Development, and PNAS, with
accumulative citations of over 42,000 times and an h-index of 89 (Google Scholar). Dr. He’s early work led to the first
identification of Wnt/β-catenin downstream targets in human cancer, and since he investigated the roles of Wnt,
BMP/TGFβ, Notch, and retinoic acid signaling in other types of human cancers. His lab was the first to to identify BMP9
(aka, GDF2) as one of the most potent osteogenic BMPs in MSCs. Furthermore, his lab demonstrated that bone tumor
cells are not only refractory to, but also stimulated by osteogenic factors, such as BMP9, suggesting that bone tumors
may be a differentiation diseases caused by genetic and/or epigenetic disruptions of terminal differentiation. In fact,
his lab has shown that non-specific differentiation agents such as retinoic acids can inhibit bone tumor growth. On the
regenerative medicine front, his lab established a large panel of reversibly immortalized adult progenitors from
multiple tissues and are studying candidate biofactors that will enhance bone fracture healing, wound healing,
cartilage damage repair, and tendon injury healing. Lastly, Dr. He has extensive expertise in developing novel and
enabling techniques to improve and facilitate biomedical research, including the widely-used AdEasy system and
numerous gene expression and silencing systems delivered by viral vectors or transposon system. More recently, his
lab has created first-in-the class short artificial regulatory RNA libraries for forward genomewide functional studies of
human diseases.
A list of his publications and research summary can be found at:
http://www.boneandcancer.org/publications/
https://pubmed.ncbi.nlm.nih.gov/?term=he+tc&sort=date

